Tag Archives: abbv

Shire Rejects AbbVie’s $46 Bil Tax-Inversion Attempt

Specialty drugmaker and IBD 50 stock Shire (SHPG) has rejected three takeover offers from U.S. big pharma AbbVie (ABBV), with the most recent valued at $46.5 billion, the companies announced Friday. Shire’s stock vaulted nearly 18% in early trading on the stock market today, to an all-time high near 225.50, while AbbVie stock was up a fraction. The two companies have been talking since early May, when AbbVie offered 39.50 British pounds per Shire

AbbVie Beats Q1 Estimates, Downplays HCV ‘Price War’

Big pharma AbbVie (ABBV) beat Q1 estimates Friday and got the Street talking when the company’s executives implied that they won’t discount their new hepatitis C regimen. Their stock was up 1% in morning trading on the stock market today. AbbVie’s earnings rose 4% above the year-earlier quarter to 71 cents a share, beating analysts’ consensus by 3 cents. Sales rose 5% to $4.56 billion, about $30 million above estimates. The company did not raise

Gilead HCV Drug May Face Price War; Rival AbbVie Up

Gilead Sciences’ (GILD) newly approved hepatitis C drug Sovaldi came under fire for its price from pharmacy benefit manager Express Scripts (ESRX) Tuesday, as rival AbbVie (ABBV) reported good data for its competing drug candidate. Gilead’s stock dropped while AbbVie’s rose on the stock market today. Bloomberg reporter Drew Armstrong said on Twitter that Express Scripts’ chief medical officer, Steve Miller, told him that the convenience of